Skip to main content

Bristol-Myers Says Celgene Deal On Track For Q3 Close After Shareholder Approval

More than 75% of the shares voted at the special meeting were voted in favor of the Celgene merger agreement.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.